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Activated phosphoinositide 3-kinase (PI3K)-
AKT signaling appears to be an obligate event
in the development of cancer. The highly related
members of the mammalian FoxO transcription
factor family, FoxO1, FoxO3, and FoxO4, repre-
sent one of several effector arms of PI3K-AKT
signaling, prompting genetic analysis of the
role of FoxOs in the neoplastic phenotypes
linked to PI3K-AKT activation. While germline
or somatic deletion of up to five FoxO alleles
produced remarkably modest neoplastic phe-
notypes, broad somatic deletion of all FoxOs
engendered a progressive cancer-prone condi-
tion characterized by thymic lymphomas and
hemangiomas, demonstrating that themamma-
lian FoxOs are indeed bona fide tumor suppres-
sors. Transcriptome and promoter analyses of
differentially affected endothelium identified
direct FoxO targets and revealed that FoxO
regulation of these targets in vivo is highly con-
text-specific, even in the same cell type. Func-
tional studies validated Sprouty2 and PBX1,
among others, as FoxO-regulated mediators of
endothelial cell morphogenesis and vascular
homeostasis.INTRODUCTION
The PI3K-AKT pathway is activated in human cancers,
commonly through genetic alterations of its many signal-
ing components. AKT and the p110a catalytic subunit of
PI3K is mutated or amplified and overexpressed in several
cancer types, and PTEN, the key PI3K-AKT pathway an-
tagonist, is also inactivated in a broad spectrum of human
cancers (Cully et al., 2006). Moreover, germline PTEN mu-
tations define three related syndromes characterized by
hamartomas, cancer, and developmental defects (Wan-
ner et al., 2001). PTEN’s diverse tumor suppressor role
in different cell lineages is further evidenced by the can-
cer-prone condition in germline and conditional Pten mu-
tant mice, which develop carcinomas of the skin, prostate,
colon, breast, and endometrium, as well as thymic lym-
phomas, among other cancers (Di Cristofano et al.,
1998; Li et al., 2002; Podsypanina et al., 1999; Suzuki
et al., 2001; Wang et al., 2003; You et al., 2002). In addition
to a direct role in tumor development, PI3K-AKT signaling
has been linked to endothelial cell (EC) homeostasis (Shio-
jima and Walsh, 2002). One of the PTEN germline mutation
syndromes, Bannayan-Zonana, is characterized by hem-
angiomas (EC hamartomas) in diverse tissues (Wanner
et al., 2001), and Pten heterozygous mice develop heman-
giomas with high penetrance (Freeman et al., 2006).
The wide range of benign to malignant phenotypes me-
diated by PI3K-PTEN-AKT signaling is consistent with the
existence of diverse downstream effectors differentiallyCell 128, 309–323, January 26, 2007 ª2007 Elsevier Inc. 309
utilized in conferring neoplastic phenotypes in distinct cell
lineages. Among such potential effectors are AKT phos-
phorylation targets TSC2, GSK3, and the FoxOs (Brunet
et al., 1999; Cross et al., 1995; Inoki et al., 2002). Recently,
much attention has been focused on TSC2 and mTOR sig-
naling as mounting pharmacological evidence suggests
that mTOR is the prime effector of the PI3K-AKT pathway,
with TSC2 serving as a central node linking LKB1-AMPK
and PI3K-AKT with mTOR (Hay, 2005). Indeed, the potent
anti-neoplastic impact of pharmacologic mTOR inhibition
raises questions as to the relevance of other AKT targets,
particularly the FoxOs, in the development of cancer. On
the other hand, the FoxO effector arm controls cell number
in Drosophila (Junger et al., 2003; Puig et al., 2003), and
the FoxO transcription factors mediate some of the growth
and survival-promoting effects of AKT signaling in ECs
(Potente et al., 2005; Skurk et al., 2004). Therefore, the
relevance of FoxO transcription factors in cancer and
their roles in normal tissue homeostasis remain to be
elucidated.
Whereas C. elegans and Drosophila contain a single
FoxO gene (DAF-16 and dFOXO, respectively), mice and
humans possess three highly related FoxO homologs
(FoxO1, FoxO3, and FoxO4) with overlapping patterns of
expression and transcriptional activities (Anderson et al.,
1998; Biggs et al., 2001; Furuyama et al., 2000). A fourth
more distantly related mammalian FoxO family member,
FoxO6, has been identified, although it appears to be reg-
ulated by distinct mechanisms and its expression is more
highly restricted to the brain (Jacobs et al., 2003; van der
Heide et al., 2005).
In cell culture-based systems, FoxO1, FoxO3, and
FoxO4 behave similarly in biochemical studies, appear to
regulate common target genes, and bind to the same
target DNA sequence (Biggs et al., 2001; Brunet et al.,
1999; Furuyama et al., 2000). Yet, mouse FoxO knockouts
have revealed unique roles for the FoxOs, such as the re-
quirement for FoxO3 in ovarian primordial follicle activation
(Castrillon et al., 2003; Hosaka et al., 2004) and FoxO1 in
vasculogenesis (Furuyama et al., 2004; Hosaka et al.,
2004). However, while the three FoxOs serve some dis-
crete functions, they likely have significant redundancies,
as they are broadly expressed during embryonic develop-
ment and in adult tissues (Furuyama et al., 2000). In this
regard, conventional genetic analysis can fail to uncover
important biological functions among closely-related
gene families, such as Rb/p107/p130 (Lee et al., 1996;
Sage et al., 2000) and p53/p63/p73 (Flores et al., 2002;
2005). Indeed, many analogies can be drawn between
the FoxO, Rb, and p53 gene families, all of which regulate
cell survival and growth and consist of members with
common physiological roles.
In the context of the linkage of FoxOs to key cancer sig-
naling pathways, the lack of an overt tumor-prone pheno-
type of the various FoxO knockout mice was somewhat
unanticipated (Castrillon et al., 2003; Hosaka et al.,
2004; Lin et al., 2004). While this may relate to the physical
and functional relatedness and overlapping expression310 Cell 128, 309–323, January 26, 2007 ª2007 Elsevier Inc.patterns of the FoxO members, it is formally possible
that the FoxO arm of the PI3K-AKT signaling network plays
a relatively minor in vivo role in cancer suppression and
vascular biology relative to other AKT downstream targets.
To address these issues, we have generated conditional
alleles for all three FoxO members with which to conduct
a systematic evaluation of FoxO family function in vivo.
RESULTS
Somatic Deletion of All Three FoxO Genes Results
in Lineage-Restricted Tumor Phenotypes
To genetically assess the cancer relevance of the FoxO
members in vivo, we generated null and conditional alleles
for all three FoxO genes (see the Supplemental Data text
and Figures S1 and S2). Exhaustive characterization of
mice bearing single and compound germline FoxO null
mutations, including FoxO1/+;FoxO3/;FoxO4/ mice,
revealed remarkably mild cancer predisposition pheno-
types as a function of advancing age or following carcino-
gen treatment (Figures S3–S6, and see Table S1 in the
Supplemental Data). The potential for redundancy and
developmental compensation among the FoxOs, coupled
with the embryonic lethality of FoxO1 deficiency (Fur-
uyama et al., 2004; Hosaka et al., 2004), prompted the
use of the inducible Mx-Cre transgene to achieve wide-
spread somatic FoxO deletion in adult tissues. The Mx1
promoter is activated by polyinosine-polycytidylic acid
(pI-pC), and pI-pC injection at 4–5 weeks of age results in
transient widespread Cre expression (Kuhn et al., 1995)
(see Mx1 promoter-directed tissue distribution of Cre
below).
To delete the FoxO genes in vivo,Mx-Cre+;FoxO1/3/4L/L
and control littermate Mx-Cre–;FoxO1/3/4L/L mice (hereaf-
ter designated as ‘‘Mx-Cre+’’ and ‘‘Mx-Cre,’’ respectively)
were injected with pI-pC. By 19–30 weeks of age,Mx-Cre+
mice developed aggressive CD4+ CD8+ lymphoblastic
thymic lymphomas, with spread to spleen, liver, and lymph
nodes (Figures 1A, 1B, and 1F, p < 0.0001). While Mx-Cre-
mediated gene deletion in the thymus was incomplete
(Kuhn et al., 1995) (Figure 1C), the lymphomas display an
enrichment of the null alleles for all three FoxO genes
(Figure 1C) accompanied by a marked decrease of FoxO
expression on both mRNA and protein levels (Figures 1D
and 1E). This and the lack of lymphomas in all other geno-
types retaining at least one FoxO allele (Figure 1A) is
consistent with the need for complete FoxO deficiency in
lymphomagenesis.
In addition, all Mx-Cre+ mice developed a striking age-
progressive hamartomatous phenotype in the EC lineage,
with widespread hemangiomas, resulting in premature
death (Figure 2A). Hemangiomas were most exaggerated
in the uterus and evident by 6–8 weeks, but greatly pro-
gressed by 30–40 weeks (Figure 2B). Histological exami-
nation revealed massive hemangiomas with intraluminal
blood and thrombi in skeletal muscle, abdominal wall,
liver, adrenal glands, bone marrow, omentum, lymph
node, and skin (Figure 2C; Figure S7A). The ECs in most
Figure 1. Thymic Lymphomas in Mice Following Somatic Deletion of Three FoxO Genes
(A) Thymic lymphoma-free survival of pI-pC-treated Mx-Cre+ mice and controls representing combined genotypes including Mx-Cre+;FoxO1L/L
(n = 11), Mx-Cre+;FoxO1/3L/L (n = 14), Mx-Cre+;FoxO1/4L/L (n = 11), and all Mx-Cre controls (n = 36). No lymphomas were observed in controls
up to 100 weeks of age.
(B) Histology and tissue infiltration of thymic lymphoma in Mx-Cre+ mouse, H&E stains. i, thymus; ii, liver, iii, lung; and iv, bone marrow. Scale bars,
200 mm (i and ii) and 100 mm (iii and iv).
(C) FoxO1, FoxO3, and FoxO4 gene deletions in thymic lymphomas and control thymi by PCR analysis.
(D) Reduction of mRNA levels of FoxO1, FoxO3, and FoxO4 in Mx-Cre+ ECs. Quantitative RT-PCR performed on Mx-Cre thymi (7 weeks), Mx-Cre+
thymi (7 weeks), and Mx-Cre+ thymic lymphomas (n = 2, 19, and 30 weeks post pI-pC); relative reduction of FoxO levels relative to Mx-Cre thymi is
shown. Error bars represent ±SE.
(E) Western blot analysis of Mx-Cre and Mx-Cre+ thymi and thymic lymphoma samples.
(F) Flow cytometric analysis of representative thymic lymphoma.lesions appeared benign; however, 9% of Mx-Cre+ mice
progressed to lethal angiosarcomas (Figure 2C).
Labeling of ECs with fluorescein-conjugated lectin re-
vealed significant increases in the numbers of ECs in af-
fected organs (Figure 2D). This proliferative phenotype
was apparent as early as 3 weeks after pI-pC injection,
prior to onset of macroscopic abnormalities in these vas-
cular beds. In contrast, ECs in the lung and kidney (where
hemangiomas do not develop following documented
FoxO deletion) did not show any abnormalities, even at27 weeks after pI-pC injection, establishing tissue-context
requirements for the FoxOs in vivo across this single line-
age (Figure 2D).
Further support for a role of the FoxOs in this vascular
phenotype stems from observations of less severe hem-
angiomas in Mx-Cre+ mice with a deficiency of only one
or two FoxO genes. By 60 weeks of age, 100% of Mx-
Cre+;FoxO1L/L females displayed mild hemangiomas in
the uterus and occasionally in perirenal fat, with no abnor-
malities in other tissues (Figure S7B). Mx-Cre+;FoxO1/4L/LCell 128, 309–323, January 26, 2007 ª2007 Elsevier Inc. 311
Figure 2. Systemic Hemangiomas in Mice Following Somatic Deletion of Three FoxO Alleles
(A) Survival of Mx-Cre+ and Mx-Cre littermate controls. Small blue squares indicate deaths due to thymic lymphomas. p value indicates comparison
between Mx-Cre+ mice (red) and all Mx-Cre controls (black).
(B) Age-dependent progression of uterine vascular lesions in Mx-Cre+ females. Scale bar, 5 mm.
(C) Histology of systemic vascular lesions, H&E stains. Genotypes are Mx-Cre+ unless otherwise noted. i, uterus, low magnification (asterisk: uterine
lumen); ii, uterine hemangioma (inset: benign endothelium of hemangioma vascular channels; arrow: endothelial cell); iii, abdominal muscle heman-
gioma; iv, liver hemangioma, Mx-Cre+ mouse; v–vi, angiosarcoma, Mx-Cre+ mouse. Scale bars, 500 mm (i and v), 400 mm (iv), 200 mm (iii), and 50 mm
(ii and vi).
(D) Fluorescence micrographs of abdominal muscle, uterine horn, and lung endothelium after vascular perfusion of fluorescein-labeled lectin (blue:
DAPI-labeled nuclei). Note increased EC density by 7 weeks in muscle and uterine horn, but not in lung, as late as 31 weeks. Scale bar, 50 mm.mice also displayed mild hemangiomas in the uterus and
occasionally in other tissues (Figure S7C), and all Mx-
Cre+;FoxO1/3 L/L mice displayed vascular abnormalities
with similar tissue distribution as Mx-Cre+;FoxO1/3/4L/L
mice (Figure S7D). Importantly, these hemangiomatous
lesions that retained either FoxO3 or FoxO4 were signifi-
cantly less severe as reflected by lack of mortality prior
to 50 weeks of age (Figure 2A). In contrast, vascular ab-
normalities were not detected in Mx-Cre+;FoxO3L/L mice312 Cell 128, 309–323, January 26, 2007 ª2007 Elsevier Inc.up to 21 weeks, germline FoxO3/;FoxO4/ mice up
to 2 years of age, and FoxO1/+;FoxO3/;FoxO4/
mice up to 40 weeks of age. These genotype-phenotype
correlations point to FoxO1 as the most potent regulator
of adult vascular homeostasis, with lesser but physiologi-
cally important contributions from the other FoxOs. In
summary, vascular lesions were much more pervasive
and severe following elimination of all three FoxOs, and
premature mortality attributable to these vascular lesions
Figure 3. Functional Studies of Thymo-
cytes and Endothelial Cells Rendered
Null for All Three FoxOs
(A) Increased proliferation and defective induc-
tion of apoptosis in Mx-Cre+ thymocytes. Thy-
mocytes from 8-week-old mice (n = 3 per geno-
type) were plated and the indicated mitogens
or apoptotic stimuli were applied. The experi-
ment was performed twice with similar results;
data from a representative experiment are
shown. Survival percentage was calculated af-
ter 18 hr of treatment (5 Gy: g-irradiation; Dex:
1 mM Dexamethasone). Data are mean ± SEM.
(B) Analysis of viability of ECs. MTT assays
were performed on Mx-Cre and Mx-Cre+
lung (n = 2) and liver (n = 3) ECs. y axis, normal-
ized response (%) per OD595. Results repre-
sent two independent experiments. Data are
mean ± SEM.was observed only in mice with somatic deletion of all
three FoxOs (Figure 2A).
Cell Biological Impact of FoxO Family Deletion
To understand how the FoxOs constrain the development
of thymic lymphoma and hemangiomas, we examined the
proliferative and survival profiles of thymocyte and ECs
derived from young cancer-free mice. Although histologi-
cally normal (data not shown), albeit with a slight reduction
in total number of thymocytes compared to Mx-Cre con-
trols (99,110,000 ± 13,590,000 versus 147,300,000 ±
20,950,000; n = 6 each; p = 0.0825), Mx-Cre+ thymocytes
exhibited altered responses to growth and death stimuli.
Upon stimulation with PMA + ionomycin, Mx-Cre+ thymo-
cytes showed increased proliferation relative to Mx-Cre
controls (Figure 3A). Proliferative enhancement was also
observed with CD3 + IL2 stimulation (Figure 3A). Con-
versely, Mx-Cre+ thymocytes were more resistant to cell
death stimuli such as g-irradiation and high-dose dexa-
methasome treatment (Figure 3A). These observations
indicate that complete loss of FoxO gene function in
thymocytes predisposes to lymphomagenesis through
cell-autonomous mechanisms that enhance cellular
proliferation and survival.
Taking advantage of efficient Mx-Cre-mediated recom-
bination in ECs in all tissue compartments examined (Fig-
ure S8) (Hayashi et al., 2004; Schneider et al., 2003) and
the organ-restricted hemangioma phenotype in Mx-Cre+
mice, we compared the biological consequences of com-
plete FoxO deletion in ECs from affected and unaffected
vascular beds in different tissues. ECs were isolated
and cultured from lung (which displayed no phenotype
in vivo) and liver (which displayed prominent hemangiom-
atous changes) from age-matched mice. The purity of
these cell preparations was >97% by flow cytometry for
CD31 and immunostaining for VE-cadherin and CD31
(Figures S9A and S9B). Efficient deletion of all three
FoxO alleles was confirmed by PCR, and western blotdocumented absence of FoxO protein in both lung and
liver ECs (Figures S9C and S9D). In vivo, absence of
mRNA for all three FoxOs in the vasculature of lung, liver,
and uterus was documented by RNA in situ hybridization
(RISH) (Figure S10).
Relative to Mx-Cre+ lung ECs, Mx-Cre+ liver ECs
showed enhanced proliferative response to stimulation
by VEGF and bFGF, two potent proangiogenic cytokines
(Bikfalvi et al., 1997; Ferrara et al., 2003). While Mx-Cre
and Mx-Cre+ lung ECs responded to VEGF similarly re-
gardless of their FoxO status, Mx-Cre+ liver ECs exhibited
a dramatic enhancement in their ability to proliferate upon
VEGF stimulation (Figure 3B; 73% versus 17.9%, p =
0.003). A similar trend was observed with bFGF stimula-
tion (p = 0.019; data not shown). Conversely,Mx-Cre+ liver
ECs were significantly less sensitive to TGF-b1, a cytokine
that induces EC cytostasis through Smad (Goumans et al.,
2003), consistent with documented direct interactions be-
tween Smad and FoxO (Seoane et al., 2004). Here, Mx-
Cre liver ECs showed reduced survival (60%) upon ex-
posure to TGF-b1, whereas Mx-Cre+ liver ECs were much
less sensitive (Figure 3B). Interestingly, lung ECs were
insensitive to TGF-b1 stimulation irrespective of FoxO sta-
tus (Figure 3B). In summary, mirroring the in vivo pheno-
types, FoxO-deficient liver ECs exhibited enhanced prolif-
erative and survival potential, while FoxO-deficient lung
ECs did not show detectable phenotypic alterations.
That FoxO exerts these biological effects in a cell-autono-
mous manner is supported by the observation of a promi-
nent hemangiomatous phenotype in skeletal muscle,
which showed a lack of Mx-Cre-mediated recombination
in the surrounding skeletal muscle fibers yet efficient
recombination in the endothelium (Figure S8K).
Integrated Transcriptome and Promoter Analysis
Identifies Direct FoxO Targets In Vivo
The above in vivo and in vitro phenotypic characterization
shows that FoxO family functions in normal tissueCell 128, 309–323, January 26, 2007 ª2007 Elsevier Inc. 313
homeostasis and cancer suppression are not only line-
age-restricted, but also organ-specific. To gain additional
insights into the mechanistic basis for such specificity,
we conducted comparative transcriptome analyses of
purified lung and liver ECs following pI-pC treatment of
age-matched Mx-Cre+ and Mx-Cre mice. We hypothe-
sized that normalization against phenotypically unaf-
fected lung ECs would provide an effective biological
filter for identifying physiologically relevant FoxO targets
versus secondary/bystander transcriptional events—the
latter would include genes whose expression responds
to FoxO regulation but who do not play a rate-limiting
role in the observed phenotypes, as well as those whose
expression might be altered by activation of Cre expres-
sion during FoxO deletion. Transcriptome profiles of liver
ECs with and without functional FoxOs were compared
with those of lung ECs (see Experimental Procedures)
to generate a list of 138 significantly differentially ex-
pressed genes—89 of which were upregulated and 49
downregulated in liver, but not in lung, ECs upon docu-
mented FoxO deletion (Table S3). Consistent with the
observed in vivo phenotypes, several differentially ex-
pressed genes have validated roles in EC biology, angio-
genesis, and tissue morphogenesis, such as XLKD1
(LYVE-1), VCAM1, angiopoietin-like 4 (ANGPTL4), adre-
nomedullin (ADM), thrombospondin1 (THBS1), and ID1,
and extracellular matrix proteins such as fibrillin (FBN1)
(Benezra, 2001; Cook-Mills, 2002; Kato et al., 2005; Le
Jan et al., 2003; Mouta Carreira et al., 2001; Ramirez
et al., 1993).
Next, we reasoned that the identification of FoxO bind-
ing elements (BEs) in differentially expressed genes would
provide more direct insights into FoxO’s actions in the ob-
served phenotypes. To that end, we conducted a system-
atic in silico analysis of the regulatory regions of these 138
genes to ascertain the presence of evolutionarily con-
served FoxO consensus BEs. For each gene, the 8 kb
to +2 kb region surrounding the transcription start site
and the 0 to +5 kb region downstream of the transcription
end site in the mouse genome was surveyed. We con-
structed a position-specific weight matrix (PWM) based
on evolutionary conservation of canonical insulin-regu-
lated FoxO targets (IGFBP1, G6PD, PEPCK) to character-
ize the FoxO binding motif (consensus = BBTRTTTTD)
(D.H.C., unpublished data). Potential FoxO BEs were fil-
tered further by cross-species conservation with two inde-
pendent methodologies (Supplemental Data). BEs that
could be identified in mouse, human, and at least one
other species were designated as a ‘‘3-species con-
served’’ BE. By requiring at least one evolutionary con-
served FoxO BE predicted by both methods, we identified
21 putative direct targets of FoxO family in liver ECs, 9 of
which were downmodulated and 12 upmodulated upon
FoxO deletion (Table 1). Interestingly, several of these
genes are highly relevant to cancer (e.g., TCF4), vascular
biology (e.g., CTGF), or both, such as ID1 and ADM, two
factors known to play critical roles in EC survival and to
promote angiogenesis during development and tumori-314 Cell 128, 309–323, January 26, 2007 ª2007 Elsevier Inc.genesis (Benezra, 2001; Kato et al., 2005; Nikitenko
et al., 2006) (see Discussion).
To validate our computational approach, we sought to
document direct binding of FoxOs on predicted BEs by
chromatin immunoprecipitation (ChIP) and to confirm ex-
pression modulation by quantitative RT-PCR and RISH
in vitro and in vivo, respectively (Table 1). Figure 4 illus-
trates the validation of Sprouty2 as a direct FoxO target.
First, using a mixture of anti-FoxO1/3/4 antibodies, DNA
fragments spanning FoxO BEs from both the proximal
and distal regions of Sprouty2 gene were more efficiently
coimmunoprecipitated in the FoxO-expressing liver ECs
versus those deficient for the FoxOs (Figure 4B). Next,
we documented, by immunoblotting and quantitative
RT-PCR, that Sprouty2 was significantly and reproducibly
downregulated in independently derived Mx-Cre+ liver
ECs, but not in Mx-Cre+ lung ECs (Figures 4C and D).
Mindful of the potential artifact introduced by culturing
EC in vitro, we next performed RISH in tissue sections to
confirm that Sprouty2 mRNA levels were comparable in
Mx-Cre and Mx-Cre+ lung EC but were significantly
downmodulated in vascular beds of affected tissues,
including liver, skeletal muscle, and uterus, in Mx-Cre+
mice 3 weeks after treatment with pI-pC (Figure 4E).
For the other targets, we conducted similar validation
studies. By RISH, 12 of 14 randomly selected putative tar-
gets exhibited transcriptional regulation by FoxO in vivo
(Figure S11). Of note, Meis1 and Klf6, which did not con-
firm by RISH, were shown to be regulated by quantitative
RT-PCR, pointing to the detection limits of RISH. More-
over, all 17 randomly selected putative targets (8 down-
modulated and 9 upmodulated) showed expression
modulation by quantitative RT-PCR in response to FoxO
deletion in culture (data not shown; Table 1). Finally, all
eight randomly selected putative targets (six downmodu-
lated and two upmodulated) were validated to be true
direct targets of FoxO by ChIP (Figure S12). Thus, eight
of eight putative targets satisfied both ChIP and expres-
sion validation (Table 1), indicating the robustness of
our integrated computational-biological approach in the
identification of direct targets of FoxOs in ECs in vivo.
FoxO Activities Are Lineage-Restricted In Vivo
Next, to address whether the spectrum of downstream ef-
fectors of the FoxOs are further dictated by cell type, we
performed similar in silico promoter analysis on a list of
354 most differentially expressed genes in the thymocyte
lineage (Table S2) and compared these profiles with those
in ECs. Strikingly, putative direct targets transcriptionally
regulated by FoxOs in thymocytes with predicted FoxO
BEs were completely nonoverlapping with those in EC lin-
eage (Table 2). A notable FoxO target in thymocytes is
p27KIP1 (CDKN1B), one of the downregulated genes with
the highest conservation score and number of 3-species
BEs (see Discussion). In other words, this in silico analysis
not only identified putative targets of direct FoxO regula-
tion, but also demonstrated in molecular terms that signal-
ing downstream of FoxO is both cell type-specific and
Table 1. FoxO Targets in Liver EC
FoxO Target
Genes
# of
BE(s)
Conservation
Score
# of 3-species
BE(s) CIS
validated by
RT-qPCR
validated
by ChIP
validated
by ISH
Downregulated FoxO
Target Genes
Spry2 10 28 5 YES YES YES
Tcf4 10 27 4 YES nd YES
Klf6 10 28 3 YES nd NO
Cited2 6 17 2 YES YES YES
Adm 5 15 2 YES YES YES
Ccrn4l 4 12 1 YES YES YES
Hmga2 1 3 1 nd nd nd
Mrc1 1 3 1 YES YES nd
Ctgf 1 3 1 YES YES YES
Upregulated FoxO
Target Genes
Meis1 10 28 4 Evi8 YES nd NO
Pbx1 11 32 3 YES YES YES
Tsc22d1 3 9 2 YES nd YES
Ccnd1 8 25 1 Ccnd1 YES nd nd
Sdpr 4 11 1 YES nd YES
Sepm 4 12 1 nd nd nd
Fbn1 4 12 1 YES nd YES
Bmper 4 12 1 YES YES YES
Rab34 3 9 1 YES nd nd
D0H4S114 3 9 1 nd nd nd
Pcolce 2 6 1 nd nd nd
Id1 1 3 1 YES nd YES
YES, validated; NO, nonvalidated; nd, not determined.tissue-specific within the same cell type. These molecular
findings provide mechanistic insights and a potential ex-
planation for the more restricted phenotypic impact of
FoxO deletion relative to activated PI3K-AKT signaling in
various organ systems.
Direct Effectors of FoxO-Regulated Endothelial
Cell Homeostasis
To elucidate further the mechanistic basis of FoxO dysre-
gulation in hemangioma development, we first focused on
Sprouty2 for biological validation, as it represented the
most significantly regulated gene with the highest number
of conserved FoxO BEs in affected liver, but not lung, EC.
Using two independent Sprouty2 shRNAs (shSpry2_1
and _2), Sprouty2 protein knockdown of 73% to 75% was
documented in primary cultures of liver ECs (Figure 5C).
Passage-associated proliferative arrest of Mx-Cre pri-
mary liver EC was reversed by Sprouty2 knockdown, con-
ferring enhanced replicative potential to Mx-Cre ECs
similar to that of FoxO-deficient Mx-Cre+ ECs (Figure 5A).
Correspondingly, increased cell cycle progression and
decreased apoptosis could be demonstrated uponSprouty2 knockdown. Specifically, the BrdU-positive
population in Mx-Cre liver EC cultures was increased
with shSpry2_1 and _2, comparable with the level of prolif-
eration inMx-Cre+ liver ECs. Importantly, further reduction
in Sprouty2 expression in Mx-Cre+ liver ECs had no ad-
ditional effects (Figure 5B). Similarly, TUNEL positivity
in Mx-Cre liver ECs decreased from 19% to 7% (p <
0.01), comparable with the reduction to 5% observed in
Mx-Cre+ liver ECs (p < 0.01). Associated with these pheno-
typic changes were differential expression of CyclinD1,
p15, and p21 as well as Bim following Sprouty2 knock-
down by shRNA (Figure 5D), reinforcing the view that
Sprouty2 functions as a negative regulator of EC prolifera-
tion and survival. Finally, in matrigel morphogenesis as-
says,Mx-Cre+ liver ECs developed a more robust tube net-
work compared with Mx-Cre liver ECs (Figure 5E). Again,
knockdown of Sprouty2 in Mx-Cre liver ECs enhanced
such VEGF-induced tube formation to levels approaching
those of Mx-Cre+ liver ECs (Figure 5E). Taken together,
these results demonstrate that Sprouty2 plays essential
roles in EC growth and tube morphogenesis and is a major
effector of FoxO function in the endothelium.Cell 128, 309–323, January 26, 2007 ª2007 Elsevier Inc. 315
Figure 4. Regulation of Sprouty2 Expression in Liver ECs by FoxOs
(A) Multiple conserved FoxO binding sites (predicted) in vicinity of Sprouty2 gene;11 kb of the genomic region is shown. Five of ten sites were con-
served in >3 species including human and mouse (Supplemental Data). Sites were scored by 10-based logarithm of the likelihood ratio between the
FoxO and background models.
(B) The FoxO BE occupancy by FoxOs. Soluble chromatin was prepared fromMx-Cre andMx-Cre+ liver ECs and immunoprecipitated with a mixture
of antibodies against the three FoxOs. Anti-pol II and anti-FoxO immunoprecipitated DNA (FoxO) was amplified, giving rise to 110 bp products
([A–D], illustrated in A).
(C) Quantitative RT-PCR analysis for Sprouty2. Expression of Sprouty2 is tightly correlated with FoxO deletion (Mx-Cre+) in liver ECs, but not in lung
ECs (**p < 0.01). Error bars = SE.
(D) Immunoblot analysis for Sprouty2. Expression of Sprouty2 is lower in FoxO deletion (Mx-Cre+) in liver ECs, but not in lung ECs, compared with
control ECs. Duplicate loading shown for each EC line.
(E) RNA in situ hybridization using antisense Sprouty2 probe tissues from Mx-Cre and Mx-Cre+ mice 3 weeks after pI-pC injection. Arrows point to
EC with strong Sprouty2 expression. Scale bar, 20 mm.To assess additional contributions from other validated
or putative direct FoxO targets listed in Table 1, knock-
down studies were conducted on an additional set of
FoxO-upregulated genes (ADM, CTGF, MRC1, and
CCRN4L) and FoxO-downregulated genes (PBX1, ID1,316 Cell 128, 309–323, January 26, 2007 ª2007 Elsevier Inc.and BMPER). These assays revealed that PBX1 exhibited
robust activities in both EC proliferation and apoptosis as-
says similar to Sprouty2, and two targets (CTGF and ADM)
showed modest effects on EC growth but not on apopto-
sis (Figure S13). Taking into account the technical caveat
of insufficient knockdown, these functional data suggest
that an additional but limited number of direct FoxO tar-
gets participate in control of EC homeostasis as well.
DISCUSSION
In this study, systematic genetic analysis provided formal
proof that the FoxOs are tumor suppressors in vivo, albeit
with a narrower tumor spectrum than might have been
predicted from previous biochemical models but in line
with inherited genetic syndromes targeting the PI3K path-
way in humans. By demonstrating regulation of distinct
sets of putative direct targets by FoxOs in thymocytes
and ECs, this study also offers molecular insights into
the highly tissue-restricted and lineage-specific actions
of FoxO in vivo.
FoxO Transcription Factors Are Functionally
Redundant in Tumor Suppression
The requirement for complete deletion of all three FoxO
loci in lymphomas, despite mosaic deletion patterns in
premalignant thymocytes, combined with the lack of an in-
creased lymphoma incidence in Mx-Cre+ animals bearing
any two floxed alleles, strongly argues for extensive func-
tional redundancy with strong selective pressure for inac-
tivation of all three FoxOs on the level of tumor formation.
With regard to the molecular basis of lymphomagenesis in
the setting of FoxO deficiency, our in vitro studies suggest
that increased cell cycle progression, as well as resistance
to proapoptotic stimuli, account for the increased inci-
dence of lymphomas in vivo. Consistent with this interpre-
tation, p27KIP1, a known T cell lymphoma suppressor gene
(Geisen et al., 2003; Kang-Decker et al., 2004; Martins and
Berns, 2002) and FoxO target (Dijkers et al., 2000; Me-
dema et al., 2000; Stahl et al., 2002), was identified as
one of the most significantly downregulated genes with
a high number of evolutionarily conserved BEs.
It is somewhat unanticipated that the tumor spectrum
following deletion of the three FoxOs is so restricted given
that misregulation of the PTEN/AKT axis results in a wide
range of tumors, including carcinomas (skin, colon, pros-
tate, etc.), which were not observed following deletion of
the three FoxOs. It is unlikely that this relates to insufficient
Mx-Cre activity in epithelial tissue compartments given
our documentation of efficient Cre-mediated recombina-
tion by both PCR and strong reporter activation in a
wide range of epithelial compartments, including skin,
mammary tissue, and GI tract (Figure S8). Furthermore,
deletion of the FoxOs using K14-Cre, which is strongly ex-
pressed in a wide range of epithelia, did not result in epi-
thelial hyperplasia or cancer in animals that were permit-
ted to age normally for up to 16 months of age (D.H.C.
and George John, unpublished data). At the same time,
we cannot exclude the possibility that a limited number
of epithelial cell types may not be targeted efficiently by
Mx-Cre and do in fact depend upon FoxO tumor suppres-
sion activity, or that certain epithelia require a longer la-
tency than the lethal neoplasias observed in our model.Such considerations gain relevance in light of FoxO1 dele-
tions in a high percentage of human prostate cancers,
although the existence of PI3K pathway mutations (e.g.,
PTEN) remains undetermined in those cancers with
FoxO1 alterations (Dong et al., 2006). While the lack of
neoplastic phenotypes in epithelial tissues does not di-
minish the importance of the FoxOs in other cell lineages,
our genetic analysis strongly suggests that other signaling
surrogates (presumably the mTOR-S6K arm) play more
prominent roles in the cancer-relevant activities of the
PI3K-AKT network in most epithelial compartments, con-
sistent with the collective data from other labs (Neshat
et al., 2001). In this regard, although relatively infrequent,
lymphomas have been documented in human PTEN-
germline syndromes, and alterations in the PTEN gene
have been reported in spontaneous lymphoid neoplasms
(Sakai et al., 1998). Moreover, mice with T cell-specific de-
letion of Pten uniformly develop T cell lymphomas (Suzuki
et al., 2001).
In regard to the FoxO-deficient vascular phenotype, it is
interesting that hemangiomas are characteristic of human
disease syndromes resulting from germline Pten muta-
tions such as Cowden’s disease and Bannayan-Zonana
syndrome (Wanner et al., 2001). Thus, the demonstration
that FoxO inactivation is sufficient to drive development
of hemangiomas suggests that misregulation of the FoxOs
is a prime mechanism by which PTEN loss leads to heman-
giomas in these patients. Along these lines, benign liver
hemangiomas associated with TSC2 deficiency display
nuclear FoxO due to inactivation of AKT pathway, whereas
TSC2 deficiency in aPten+/ background leads to very ag-
gressive lethal hemangiomas wherein FoxOs localize to
the cytosol (Manning et al., 2005). Finally, such restricted
cancer phenotypes following deletion of all three FoxOs
reveals surprisingly tissue-specific roles for PTEN/AKT sig-
naling surrogates in distinct lineages. These observations
highlight the value of conducting in vivo genetic studies.
The FoxO Family Regulates Endothelial Cell
Homeostasis
Hemangiomas occurred systemically but were most se-
vere in the uterus, which is perhaps a consequence of
the cyclic vascular remodeling that occurs in this organ
(Heryanto and Rogers, 2002). Along similar lines, it is
tempting to speculate that the hemangioma-susceptible
nature of the liver and muscle, but not the pulmonary vas-
culature, may reflect the remodeling and regenerative ca-
pacity of these organ systems in the setting of injury (e.g.,
hepatectomy) or physiologic stress (e.g., exercise). Much
less severe lesions were observed in Mx-Cre+;FoxO1L/L
mice but not in FoxO3 or FoxO4 nullizygous mice, arguing
that FoxO1 is the most physiologically important regulator
of endothelial stability. Nonetheless, successive inactiva-
tion of FoxO3 and/or FoxO4 in addition to FoxO1 resulted
in hemangioma phenotypes of increasing severity, clearly
indicating that both FoxO3 and FoxO4 also contribute to
endothelial growth suppression in vivo.Cell 128, 309–323, January 26, 2007 ª2007 Elsevier Inc. 317
Table 2. FoxOTargets in Thymocyte
FoxO Target Genes # of BE(s) Conservation Score # of 3-species BE(s) CIS
Downregulated FoxO
Target Genes
Npas3 10 29 6
Cdh8 10 31 4
Myef2 6 16 3
Cdkn1b 5 14 3
Dlgap1 10 29 2 Btl14
Tmem25 8 23 2
Lrrtm3 7 20 2
Tbx4 5 14 2
Kcnj2 5 16 2
AJ430384 4 12 2
Efna5 4 12 2
Rest 8 22 1
Odz3 7 19 1
Dpf3 5 15 1
Bag5 5 13 1
Cacna1e 4 11 1
Olfm3 3 9 1
Gas7 3 9 1
Tmem71 3 9 1
Znrf4 3 8 1
Aqp7 2 6 1
C730036D15Rik 2 6 1
Kcnip4 2 6 1
Usp3 2 6 1 Evi98
Myo1e 2 6 1
Tgfbr2 2 6 1
Cdh23 2 6 1
Trem2 2 6 1
Klc3 1 3 1
Cryab 1 3 1
Cacna2d2 1 3 1
Ncbp2 1 3 1
Dmrt3 1 3 1
Upregulated FoxO
Target Genes
Sox5 25 71 6 Btl27
Rora 14 39 4
Cacna2d1 13 37 3
Creb5 11 31 3
Igsf4d 11 32 3
Srgap3 10 29 3
Pfkfb2 7 19 3318 Cell 128, 309–323, January 26, 2007 ª2007 Elsevier Inc.
Table 2. Continued
FoxO Target Genes # of BE(s) Conservation Score # of 3-species BE(s) CIS
Pacs1 6 17 3
Sox4 5 14 3 Evi16
Mmp16 11 33 2
Slc12a1 9 25 2
Dcamkl1 6 17 2
4931406I20Rik 6 17 2 4931406I20Rik
Scn5a 5 15 2
Sorl1 4 12 2
Pou4f3 4 11 2
Shox2 11 32 1
Hoxd12 6 19 1
Id4 6 17 1
Hapln1 6 17 1
Slc12a1 5 14 1
Golph4 5 14 1
Slc24a2 5 15 1
Ppp1r9a 5 15 1
Barx2 5 15 1
Ddx47 4 11 1
Abcd2 4 12 1
Npy2r 3 9 1
Shrm 3 8 1
Igfbp3 3 8 1
Flt1 2 6 1
Dyx1c1 2 5 1
D14Ertd171e 2 5 1Sprouty2 Is a Major Direct Target of FoxO
in Endothelial Cells
The rationale for emphasizing Sprouty2 for our in-depth
biological validation studies rested on the high number
of predicted FoxO DNA BEs, its known functions in
branching morphogenesis, and its documented, albeit
poorly understood, roles in growth inhibition. While
Sprouty2 is not the sole mediator of the FoxO effects on
EC growth and survival (see below), our studies prove
that it is a major effector, as knockdown of Sprouty2 mim-
icked many of the phenotypic consequences of triple
FoxO deletion. The FoxO-Sprouty2 link gains further ap-
peal in light of previous work showing that the Drosophila
Sprouty homolog functions as an antagonist of receptor
tyrosine kinase (RTK) signaling pathways that regulate
branching morphogenesis of airways (Hacohen et al.,
1998; Kramer et al., 1999), a process with obvious paral-
lels to vasculogenesis. Sprouty and its mammalian homo-
logs (Sprouty1–4) are general inhibitors of RTK signalingthat function by dampening the RAS-RAF-MEK pathway
(Gross et al., 2001; Reich et al., 1999). Finally, on a
more speculative level, it was recently demonstrated
that Sprouty2 protein contains iron-sulfur complexes
and assembles into large 24 subunit particles that store
electrical charge and thus could serve as intercellular re-
dox sensors (Wu et al., 2005). Furthermore, Sprouty2 is
subject to nitrosylation by nitric oxide (NO) (Wu et al.,
2005), consistent with studies showing that forced ex-
pression of NO synthase phenocopies the Sprouty muta-
tion in flies (Wingrove and O’Farrell, 1999). How these pro-
vocative findings relate to RTK inhibition remain to be
determined, but the link between Sprouty proteins and
NO is especially intriguing, given the importance of NO
as a regulator of vascular endothelium and response to
hypoxia, and given the fact that endothelium is a major
site of NO synthesis. Thus, many lines of evidence sup-
port the view that Sprouty2 is a critical focal point for
pathways relevant to vascular biology.Cell 128, 309–323, January 26, 2007 ª2007 Elsevier Inc. 319
Figure 5. FoxOs Regulate Liver EC Angiogenic Response through Sprouty2
(A) Growth advantage of Mx-Cre+ over Mx-Cre liver ECs after 10 days culture. Sprouty2 knockdown in Mx-Cre liver ECs had a similar effect. Scale
bar, 15mm.
(B) TUNEL and BrdU. Knockdown of Sprouty2 (shSpry2_1 and _2, shRNAs) in Mx-Cre liver ECs phenocopies cell growth and apoptosis phenotypes
in Mx-Cre+ liver ECs; (*) indicates p < 0.01. Error bars = SE.
(C) Knockdown of endogenous Sprouty2 protein expression in Mx-Cre liver ECs by shSpry2. Two independent replicates are shown. Band densities
were measured by ImageJ and normalized to tubulin. Ratio indicates normalized values over that of control (vector-infected Mx-Cre EC).
(D) Correlation of Sprouty2 expression with cyclinD1, p21, p15, and Bim level in liver ECs by quantitative RT-PCR. Knockdown of Sprouty2 with two
different shRNAs (shSpry2_1 and _2) recapitulates above differences for cyclinD1, p21, p15, and Bim relative to parental untreated and vector-only
controls (lower panels). Results shown are from triplicate experiments. Error bars = SE.
(E) VEGF-induced tube formation in liver ECs. Scale bar = 100 mm. Average tubule length/HPF (±SD) measured by ImageJ software in multiple
microscopic fields was plotted (*p < 0.01 versus vector-infected Mx-Cre EC).320 Cell 128, 309–323, January 26, 2007 ª2007 Elsevier Inc.
At the same time, despite its potent negative regulatory
effect on EC growth and survival, previous analysis of
Sprouty2 knockout mice did not show high incidence of
hemangioma (Taketomi et al., 2005; Shim et al., 2005). Ab-
sence of apparent hemangiomas in Sprouty2 knockout
mice may therefore reflect that the FoxO null hemangioma
phenotype may require the collaborative impact of addi-
tional FoxO target genes. Indeed, our functional analysis
on an additional set of FoxO-target genes supports this
view, pointing to important contributions of PBX1 in
FoxO-regulated vascular biology in vivo (Figure S13).
In summary, by utilizing the in vivo system for somatic
deletion of FoxO in multiple cell lineages, which resulted
in clear phenotype-genotype correlations, and by employ-
ing computational prediction of FoxO BEs, we obtained
evidence that the FoxOs effect unique biological conse-
quences in different cell or tissue contexts via modulation
of distinct downstream targets. These observations
should motivate further analysis of FoxO targets for the
development of novel points of therapeutic intervention
in cancer and vascular disease but should also emphasize
that the proper deployment of such therapies requires
a systematic dissection of these targets in specific line-
ages and of the tissue contexts of these lineages.
EXPERIMENTAL PROCEDURES
Targeting Constructs, Generation, and Analysis of Mice
See Supplemental Data.
Immunohistochemistry and Immunofluorescence
Formalin-fixed, paraffin-embedded sections were used. For stains of
pituitary tumors, sections were incubated with rabbit polyclonal anti-
bodies to prolactin, GH, or ACTH (obtained through NHPP, NIDDK,
and Dr. A.F. Parlow) followed by incubation with HRP-goat anti-rabbit
IgG (Zymed) or with monoclonal antibodies to TSH, FSH, and LH (Lab-
Vision/Neomarkers) utilizing the Histomouse-MAX kit (Zymed). In all
cases, sections were then incubated with DAB and counterstained
with hematoxylin. To visualize functional vasculature, we intravenously
injected deeply anesthetized mice with 100 mg FITC-labeled tomato
lectin (Vector Laboratories) and perfused the hearts with 4% parafor-
maldehyde; tissues were then frozen in OCT medium. Images were
acquired at a 0.5 mm thickness interval using a Zeiss inverted micro-
scope (Axiovert) with automated stage, and image deconvolution
was carried out with the nearest neighbor algorithm.
Thymocyte Isolation, Proliferation, and Apoptosis
For analysis of thymocytes, fresh thymus was passed through a cell
strainer (Becton Dickinson) in order to produce single cell suspensions
for analysis, then resuspended in RPMI-1640 media containing 10%
fetal calf serum. For thymocyte proliferation assays, cells were seeded
in 96-well plates at 13 105 cells per well and subjected to the following
conditions: no mitogen, PMA (1 ng/ml) + ionomycin (50 ng/ml), and
3 mg/ml anti-CD3e (eBioscience) + 100 U IL-2. Cells were grown for
48 hr, and pulsed with 1 mCi [3H]-thymidine (Amersham) for the last
16 hr. Incorporated [3H]-thymidine was measured using the 1450 Mi-
croBeta Trilux Scintillation and Luminescence Counter. For analysis
of apoptosis, thymocytes were plated in 12-well plates (1 3 106 cells
per well) and treated with 5 Gy g-irradiation or 1 mM dexamethasone
for 18 hr. Cell viability was determined by staining the cells with propi-
dium iodide and performing flow cytometric analysis.Flow Cytometric Analysis
Single cell suspensions of thymus or EC were incubated with the
following monoclonal antibodies: anti-CD4 (PE- or FITC-conjugated),
anti-CD8 (PE- or APC-conjugated), anti-Mac-1-FITC, anti-CD3-PE, anti-
CD25-APC, anti-CD44-PE, anti-Gr-1-PE, anti-CD19-APC, and anti-
CD31-FITC (all from PharMingen). Flow cytometry analysis was
performed on freshly stained samples.
Isolation and Characterization of Endothelial Cells, Microarray
Analysis, and FoxO DNA Binding Element Studies
See Supplemental Data.
Quantitative RT-PCR Analysis
RNA was harvested using Trizol (Invitrogen) and the RNeasy kit (Qia-
gen). RNA was treated with RQ1 RNase-freeDNase (Promega), and
cDNA was prepared utilizing Superscript II Rnase H-Reverse tran-
scriptase (Invitrogen). Quantitative RT-PCR was performed on cDNA
samples utilizing the Quantitect SYBR Green PCR kit (Qiagen) and
was run on the Stratagene Mx3000P. Primer sequences are available
upon request.
Western Blot Analysis
Tissues and cells were lysed with RIPA buffer (20 mM Tris [pH 7.5],
150 mM NaCl, 1% Nonidet P-40, 0.5% Sodium Deoxycholate, 1 mM
EDTA, 0.1% SDS) containing complete mini protease inhibitors
(Roche). Western blots were performed utilizing 50 mg of lysate protein,
incubated with the following antibodies: anti-FKHR(FoxO1)/AFX
(FoxO4) (Cell Signaling Technology) and anti-FKHRL1(FoxO3) (Up-
state Biotechnology).
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.cell.com/cgi/content/full/128/2/309/DC1/.
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